Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;70(9):3341-3345.
doi: 10.4103/ijo.IJO_228_22.

Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy

Abhijeet Beniwal  1 , Nawazish Shaikh  1 , Rohan Chawla  1 , Shorya Vardhan Azad  1 , Vinod Kumar  1 , Rajpal Vohra  1
Affiliations

Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy

Abhijeet Beniwal et al. Indian J Ophthalmol. 2022 Sep.

Abstract

Purpose: To study the effect of subthreshold micropulse yellow laser treatment on central serous chorioretinopathy (CSC) and to compare two laser protocols. As per our knowledge, there are no studies comparing the two protocols of subthreshold laser.

Methods: Twenty-three patients with non-resolving CSC of at least three months duration were treated with subthreshold laser (577 nm). Ten patients were treated with 5% duty cycle (group A) and 13 patients with 10% duty cycle (group B). At one month, best corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF), choroidal thickness (CT) and choroidal vascularity index (CVI) were evaluated.

Results: In group A, BCVA improved from 0.508 ± 504 to 0.174 ± 0.171 (P = 0.0058), CMT improved from 349.8 ± 168.9 micrometers (μm) to 183.3 ± 70.312 μm (P = 0.0093) and SRF reduced from 202.4 ± 158.024 to 43.8 ± 46.599 μm (P = 0.0069). In group B, BCVA improved from 0.437 ± 0.426 to 0.289 ± 0.470 (P = 0.0026), CMT improved from 280.846 ± 72.668 to 196.769 ± 72.62 μm (P = 0.0002) and SRF reduced from 110.385 ± 57.687 μm to 52.538 ± 52.111 μm (P = 0.0064). No significant difference was found in BCVA and CMT between the groups (P = 0.8716 and P = 0.8523, respectively). CSC completely resolved in 50% of cases in group A and in 69.2% of cases in group B. This difference was not statistically significant (0.423); however, the odds ratio of resolution was 2.25 times more with 10% duty cycle. No change was observed on fundus autofluorescence (FAF) following laser.

Conclusion: Subthreshold micropulse laser can lead to resolution of SRF in 60.87% of cases (groups A and B combined). Ten per cent duty cycle had higher odds of resolution without causing any RPE damage.

Keywords: Central serous chorioretinopathy; duty cycle; subthreshold micropulse laser.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
(a) SS-OCT image with choroid ma rked from RPE–Bruch’s complex to sclero-choroidal junction (between yellow lines) using freehand tool on Image J software. (b) Same image converted to 8 bit and binarized using Niblack’s auto local threshold tool of Image J software
Figure 2
Figure 2
(a) Fluorescein and indocyanine green angiography image of a patient of group A showing leak (arrow). (b) Pre-treatment SS-OCT image. Central macular thickness, subretinal fluid height and choroidal thickness beneath fovea have been measured. (c) Post-treatment SS-OCT image showing resolution of CSC. The central macular thickness and choroidal thickness beneath the fovea have been measured
Figure 3
Figure 3
(a) Fluorescein and indocyanine green angiography image of a patient of group B showing leak (arrow). (b) Pre-treatment SS-OCT image. Central macular thickness, subretinal fluid height and choroidal thickness beneath the fovea have been measured. (c) Post-treatment SS-OCT image showing resolution of CSC. The central macular thickness and choroidal thickness beneath fovea have been measured
See this image and copyright information in PMC

Comment in

References

    1. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy:A review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–14. - PubMed
    1. Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, et al. Central serous chorioretinopathy:Pathogenesis and management. Clin Ophthalmol (Auckland, NZ) 2019;13:2341. - PMC - PubMed
    1. Loo RH, Scott IU, Flynn HW, Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. - PubMed
    1. Rahimy E, Pitcher JD, III, Hsu J, Adam MK, Shahlaee A, Samara WA, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior) Retina. 2018;38:962–9. - PubMed
    1. Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI):A randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303. - PubMed